Think of your most difficult patient – the one you try to motivate and work so hard with to develop a realistic treatment plan with achievable and measurable goals. Week after week, you see this patient struggle, sinking deeper into hopelessness as their health and quality of life continue to worsen. What if there was something else you could do that could change their outlook and their life? The solution is as simple as an automated program.
| Digital ExclusiveThe Conspiracy That Fueled the Opioid Crisis
While growing awareness of the opioid crisis has spurred ongoing changes at both the policy and practice level, it might not have been necessary if not for the relationship between opioid manufacturers and advocacy groups, according to a new report from the U.S. Senate Homeland Security & Governmental Affairs Committee.
Fueling an Epidemic: Exposing the Financial Ties Between Opioid Manufacturers and Third-Party Advocacy Groups "provides the first comprehensive snapshot of the financial connections between opioid manufacturers and advocacy groups and professional societies operating in the area of opioids policy," according to the executive summary, which outlines the disturbing nature of the "connections" and their impact on the opioid epidemic:
"Disclosures from Purdue Pharma L.P., Janssen Pharmaceuticals, Inc., Mylan N.V., Depomed, Inc., and Insys Therapeutics, Inc. ... describe nearly $9 million in payments from these manufacturers to 14 outside groups working on chronic pain and other opioid-related issues between 2012 and 2017. In addition, physicians affiliated with these groups accepted more than $1.6 million in payments from the five manufacturers between 2013 and the present."
![](https://acupuncturetoday.com/_images/content/33456__1_1_2438.jpg)
"Initiatives from the groups in this report often echoed and amplified messages favorable to increased opioid use — and ultimately, the financial interests of opioid manufacturers. These groups have issued guidelines and policies minimizing the risk of opioid addiction and promoting opioids for chronic pain, lobbied to change laws directed at curbing opioid use, and argued against accountability for physicians and industry executives responsible for overprescription and misbranding."
Learn more and download the complete report by clicking here.